Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
Pre-publication versions of this article are available by contacting email@example.com.
|5 May 2018||Submitted||Original manuscript|
|5 Jul 2018||Reviewed||Reviewer Report - Joung Jang|
|17 Sep 2018||Reviewed||Reviewer Report - Junji Furuse|
|17 Oct 2018||Reviewed||Reviewer Report - Masashi Kanai|
|29 Nov 2018||Author responded||Author comments - Markus Moehler|
|Resubmission - Version 2|
|29 Nov 2018||Submitted||Manuscript version 2|
|6 Dec 2018||Reviewed||Reviewer Report - Masashi Kanai|
|12 Dec 2018||Author responded||Author comments - Markus Moehler|
|Resubmission - Version 3|
|12 Dec 2018||Submitted||Manuscript version 3|
|13 Dec 2018||Editorially accepted|
|11 Jan 2019||Article published||10.1186/s12885-018-5223-7|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.